{"name":"Janssen Research & Development, LLC","slug":"janssen-research-development-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":71,"colorKey":"oncology","drugs":[{"name":"AAVCAGsCD59","genericName":"AAVCAGsCD59","slug":"aavcagscd59","indication":"Other","status":"phase_1"},{"name":"CNTO 6785","genericName":"CNTO 6785","slug":"cnto-6785","indication":"Other","status":"phase_2"},{"name":"14C-aticaprant","genericName":"14C-aticaprant","slug":"14c-aticaprant","indication":"Other","status":"phase_1"},{"name":"AL-335","genericName":"AL-335","slug":"al-335","indication":"Other","status":"phase_2"},{"name":"ARV Background Regimen","genericName":"ARV Background Regimen","slug":"arv-background-regimen","indication":"Other","status":"phase_2"},{"name":"Active reference comparator","genericName":"Active reference comparator","slug":"active-reference-comparator","indication":"Other","status":"phase_3"},{"name":"Canagliflozin 300 mg","genericName":"Canagliflozin 300 mg","slug":"canagliflozin-300-mg","indication":"Other","status":"marketed"},{"name":"Candin","genericName":"Candin","slug":"candin","indication":"Other","status":"discontinued"},{"name":"Cilta-cel","genericName":"Cilta-cel","slug":"cilta-cel","indication":"Other","status":"marketed"},{"name":"JNJ-67835989","genericName":"JNJ-67835989","slug":"jnj-67835989","indication":"Other","status":"phase_1"},{"name":"ODV 100 mg","genericName":"ODV 100 mg","slug":"odv-100-mg","indication":"Other","status":"phase_1"},{"name":"Treatment C (placebo)","genericName":"Treatment C (placebo)","slug":"treatment-c-placebo","indication":"Used as control comparator in clinical trials across all therapeutic areas","status":"marketed"},{"name":"Xilonix","genericName":"Xilonix","slug":"xilonix","indication":"Other","status":"discontinued"},{"name":"11C-JNJ-63779586","genericName":"11C-JNJ-63779586","slug":"11c-jnj-63779586","indication":"Other","status":"phase_1"},{"name":"14C-JNJ-56136379","genericName":"14C-JNJ-56136379","slug":"14c-jnj-56136379","indication":"Other","status":"phase_1"},{"name":"14C-bleximenib","genericName":"14C-bleximenib","slug":"14c-bleximenib","indication":"Other","status":"phase_1"},{"name":"14C-lazertinib","genericName":"14C-lazertinib","slug":"14c-lazertinib","indication":"Other","status":"phase_1"},{"name":"18F-JNJ-64326067","genericName":"18F-JNJ-64326067","slug":"18f-jnj-64326067","indication":"Other","status":"phase_1"},{"name":"AAV5-hRKp.RPGR","genericName":"AAV5-hRKp.RPGR","slug":"aav5-hrkp-rpgr","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_2"},{"name":"ARX517","genericName":"ARX517","slug":"arx517","indication":"Other","status":"phase_1"},{"name":"Abiraterone: Treatment D","genericName":"Abiraterone: Treatment D","slug":"abiraterone-treatment-d","indication":"Other","status":"phase_1"},{"name":"Ami-HC","genericName":"Ami-HC","slug":"ami-hc","indication":"Other","status":"phase_1"},{"name":"Ami-HC-CF","genericName":"Ami-HC-CF","slug":"ami-hc-cf","indication":"Other","status":"phase_1"},{"name":"Ami-LC","genericName":"Ami-LC","slug":"ami-lc","indication":"Other","status":"phase_1"},{"name":"Antidepressant","genericName":"Antidepressant","slug":"antidepressant","indication":"Other","status":"marketed"},{"name":"Apixaban 2.5 mg","genericName":"Apixaban 2.5 mg","slug":"apixaban-2-5-mg","indication":"Other","status":"marketed"},{"name":"Aticaprant Therapeutic Dose","genericName":"Aticaprant Therapeutic Dose","slug":"aticaprant-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"Bermekimab Monoclonal Antibody","genericName":"Bermekimab Monoclonal Antibody","slug":"bermekimab-monoclonal-antibody","indication":"Inflammatory conditions (Phase 2 development)","status":"phase_2"},{"name":"Best Supportive Care (BSC)","genericName":"Best Supportive Care (BSC)","slug":"best-supportive-care-bsc","indication":"Other","status":"phase_3"},{"name":"Bridging Therapy","genericName":"Bridging Therapy","slug":"bridging-therapy","indication":"Other","status":"phase_2"},{"name":"Canagliflozin tablets","genericName":"Canagliflozin tablets","slug":"canagliflozin-tablets","indication":"Other","status":"phase_1"},{"name":"Canagliflozin, 100 mg","genericName":"Canagliflozin, 100 mg","slug":"canagliflozin-100-mg","indication":"Other","status":"marketed"},{"name":"Dapoxetine hydrochloride","genericName":"Dapoxetine hydrochloride","slug":"dapoxetine-hydrochloride","indication":"Premature ejaculation in men aged 18-64 years","status":"phase_3"},{"name":"Dexamethasone 20 mg","genericName":"Dexamethasone 20 mg","slug":"dexamethasone-20-mg","indication":"Other","status":"marketed"},{"name":"Esketamine 56 mg","genericName":"Esketamine 56 mg","slug":"esketamine-56-mg","indication":"Other","status":"marketed"},{"name":"Genetic: AAV5-hRKp.RPGR","genericName":"Genetic: AAV5-hRKp.RPGR","slug":"genetic-aav5-hrkp-rpgr","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","genericName":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","slug":"genetic-aav5-hrkp-rpgr-intermediate-dose","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Genetic: AAV5-hRKp.RPGR Low Dose","genericName":"Genetic: AAV5-hRKp.RPGR Low Dose","slug":"genetic-aav5-hrkp-rpgr-low-dose","indication":"X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations","status":"phase_3"},{"name":"Guselkumab Intravenous","genericName":"Guselkumab Intravenous","slug":"guselkumab-intravenous","indication":"Other","status":"phase_3"},{"name":"HD quadrivalent influenza vaccine","genericName":"HD quadrivalent influenza vaccine","slug":"hd-quadrivalent-influenza-vaccine","indication":"Prevention of influenza in adults aged 65 years and older","status":"phase_3"},{"name":"Imvanex","genericName":"Imvanex","slug":"imvanex","indication":"Other","status":"phase_1"},{"name":"JNJ-42756493: Part 1","genericName":"JNJ-42756493: Part 1","slug":"jnj-42756493-part-1","indication":"Other","status":"phase_1"},{"name":"JNJ-54861911","genericName":"JNJ-54861911","slug":"jnj-54861911","indication":"Other","status":"phase_1"},{"name":"JNJ-54861911-Therapeutic Dose","genericName":"JNJ-54861911-Therapeutic Dose","slug":"jnj-54861911-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"JNJ-55375515 Dose Level 5","genericName":"JNJ-55375515 Dose Level 5","slug":"jnj-55375515-dose-level-5","indication":"Other","status":"phase_1"},{"name":"JNJ-61393215","genericName":"JNJ-61393215","slug":"jnj-61393215","indication":"Other","status":"phase_2"},{"name":"JNJ-63623872 600 mg","genericName":"JNJ-63623872 600 mg","slug":"jnj-63623872-600-mg","indication":"Other","status":"phase_1"},{"name":"JNJ-63723283","genericName":"JNJ-63723283","slug":"jnj-63723283","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 1","genericName":"JNJ-64565111 Dose Level 1","slug":"jnj-64565111-dose-level-1","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 2","genericName":"JNJ-64565111 Dose Level 2","slug":"jnj-64565111-dose-level-2","indication":"Other","status":"phase_2"},{"name":"JNJ-64565111 Dose Level 3","genericName":"JNJ-64565111 Dose Level 3","slug":"jnj-64565111-dose-level-3","indication":"Other","status":"phase_2"},{"name":"JNJ-64991524 Dose Level 8","genericName":"JNJ-64991524 Dose Level 8","slug":"jnj-64991524-dose-level-8","indication":"Other","status":"phase_1"},{"name":"JNJ-67571244","genericName":"JNJ-67571244","slug":"jnj-67571244","indication":"Other","status":"phase_1"},{"name":"JNJ-67953964","genericName":"JNJ-67953964","slug":"jnj-67953964","indication":"Other","status":"phase_2"},{"name":"JNJ-68284528","genericName":"JNJ-68284528","slug":"jnj-68284528","indication":"Other","status":"phase_2"},{"name":"JNJ-78934804","genericName":"JNJ-78934804","slug":"jnj-78934804","indication":"Other","status":"phase_2"},{"name":"JNJ-95475939","genericName":"JNJ-95475939","slug":"jnj-95475939","indication":"Other","status":"phase_2"},{"name":"Ketoconazole 200 mg","genericName":"Ketoconazole 200 mg","slug":"ketoconazole-200-mg","indication":"Other","status":"phase_1"},{"name":"Matching Placebo to JNJ-77242113","genericName":"Matching Placebo to JNJ-77242113","slug":"matching-placebo-to-jnj-77242113","indication":"Other","status":"phase_3"},{"name":"Matching Placebo to Ustekinumab","genericName":"Matching Placebo to Ustekinumab","slug":"matching-placebo-to-ustekinumab","indication":"Other","status":"phase_3"},{"name":"Matching placebo to Seltorexant","genericName":"Matching placebo to Seltorexant","slug":"matching-placebo-to-seltorexant","indication":"Matching placebo control for Seltorexant clinical trials (not a therapeutic agent)","status":"phase_3"},{"name":"PP6M injection Dose 1","genericName":"PP6M injection Dose 1","slug":"pp6m-injection-dose-1","indication":"Contraception in women of reproductive age","status":"phase_3"},{"name":"Placebo (20% Intralipid)","genericName":"Placebo (20% Intralipid)","slug":"placebo-20-intralipid","indication":"Other","status":"phase_3"},{"name":"Placebo and prednisone","genericName":"Placebo and prednisone","slug":"placebo-and-prednisone","indication":"Active comparator arm in phase 3 clinical trial (specific indication unknown)","status":"phase_3"},{"name":"Placebo for Niraparib","genericName":"Placebo for Niraparib","slug":"placebo-for-niraparib","indication":"Control arm in Phase 3 clinical trial for Niraparib","status":"phase_3"},{"name":"Placebo for guselkumab","genericName":"Placebo for guselkumab","slug":"placebo-for-guselkumab","indication":"Other","status":"phase_3"},{"name":"Sulphonylruea","genericName":"Sulphonylruea","slug":"sulphonylruea","indication":"Other","status":"phase_3"},{"name":"Sulphonylurea","genericName":"Sulphonylurea","slug":"sulphonylurea","indication":"Other","status":"marketed"},{"name":"Treatment C: abiraterone acetate","genericName":"Treatment C: abiraterone acetate","slug":"treatment-c-abiraterone-acetate","indication":"Other","status":"phase_1"},{"name":"Treatment sequence 2","genericName":"Treatment sequence 2","slug":"treatment-sequence-2","indication":"Other","status":"phase_1"},{"name":"[18F]MNI-1020","genericName":"[18F]MNI-1020","slug":"18f-mni-1020","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":20,"colorKey":"immunology","drugs":[{"name":"Dara SC","genericName":"Dara SC","slug":"dara-sc","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab IV","genericName":"Daratumumab IV","slug":"daratumumab-iv","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab SC","genericName":"Daratumumab SC","slug":"daratumumab-sc","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"VEN","genericName":"VEN","slug":"ven","indication":"Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory","status":"marketed"},{"name":"5-Flurouracil","genericName":"5-Flurouracil","slug":"5-flurouracil","indication":"Colorectal cancer","status":"phase_3"},{"name":"Abiraterone Acetate (AA)","genericName":"Abiraterone Acetate (AA)","slug":"abiraterone-acetate-aa","indication":"Metastatic castration-resistant prostate cancer (mCRPC)","status":"phase_3"},{"name":"Abiraterone acetate and prednisone","genericName":"Abiraterone acetate and prednisone","slug":"abiraterone-acetate-and-prednisone","indication":"Metastatic castration-resistant prostate cancer","status":"phase_3"},{"name":"Abiraterone: Treatment A","genericName":"Abiraterone: Treatment A","slug":"abiraterone-treatment-a","indication":"Prostate cancer","status":"phase_1"},{"name":"Abiraterone: Treatment C","genericName":"Abiraterone: Treatment C","slug":"abiraterone-treatment-c","indication":"Prostate cancer","status":"phase_1"},{"name":"Amivantamab IV","genericName":"Amivantamab IV","slug":"amivantamab-iv","indication":"Non-small cell lung cancer","status":"phase_2"},{"name":"Amivantamab Intravenous","genericName":"Amivantamab Intravenous","slug":"amivantamab-intravenous","indication":"Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations","status":"phase_3"},{"name":"Amivantamab SC","genericName":"Amivantamab SC","slug":"amivantamab-sc","indication":"Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation","status":"phase_2"},{"name":"BCG Vesiculture","genericName":"BCG Vesiculture","slug":"bcg-vesiculture","indication":"Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma","status":"phase_3"},{"name":"Dara IV","genericName":"Dara IV","slug":"dara-iv","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Daratumumab SC: daratumumab + rHuPH20","genericName":"Daratumumab SC: daratumumab + rHuPH20","slug":"daratumumab-sc-daratumumab-rhuph20","indication":"Multiple myeloma (newly diagnosed and relapsed/refractory)","status":"phase_3"},{"name":"Leucovorin calcium/Levoleucovorin","genericName":"Leucovorin calcium/Levoleucovorin","slug":"leucovorin-calcium-levoleucovorin","indication":"Metastatic colorectal cancer (in combination with fluorouracil)","status":"phase_3"},{"name":"PCI-32765 (Ibrutinib)","genericName":"PCI-32765 (Ibrutinib)","slug":"pci-32765-ibrutinib","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Standard of Care Treatment","genericName":"Standard of Care Treatment","slug":"standard-of-care-treatment","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TAR-200","genericName":"TAR-200","slug":"tar-200","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"},{"name":"TAR-210","genericName":"TAR-210","slug":"tar-210","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"respiratory","drugs":[{"name":"Cosentyx","genericName":"Cosentyx","slug":"cosentyx","indication":"Ankylosing spondylitis","status":"marketed"},{"name":"Guselkumab Dose 1","genericName":"Guselkumab Dose 1","slug":"guselkumab-dose-1","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Guselkumab Subcutaneous","genericName":"Guselkumab Subcutaneous","slug":"guselkumab-subcutaneous","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"JNJ-79635322","genericName":"JNJ-79635322","slug":"jnj-79635322","indication":"Psoriasis","status":"phase_3"},{"name":"Nipocalimab SC-LIV","genericName":"Nipocalimab SC-LIV","slug":"nipocalimab-sc-liv","indication":"Generalized myasthenia gravis (gMG)","status":"phase_3"},{"name":"Ustekinumab - Half-Standard Dosage","genericName":"Ustekinumab - Half-Standard Dosage","slug":"ustekinumab-half-standard-dosage","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Ustekinumab IV","genericName":"Ustekinumab IV","slug":"ustekinumab-iv","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"Ustekinumab SC","genericName":"Ustekinumab SC","slug":"ustekinumab-sc","indication":"Plaque psoriasis","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"neuroscience","drugs":[{"name":"PP1M","genericName":"PP1M","slug":"pp1m","indication":"Schizophrenia","status":"phase_3"},{"name":"Atomoxetine (ATO)","genericName":"Atomoxetine (ATO)","slug":"atomoxetine-ato","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults","status":"marketed"},{"name":"Concerta AG formulation","genericName":"Concerta AG formulation","slug":"concerta-ag-formulation","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_2"},{"name":"Concerta EG formulation","genericName":"Concerta EG formulation","slug":"concerta-eg-formulation","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_2"},{"name":"Intravenous Esketamine","genericName":"Intravenous Esketamine","slug":"intravenous-esketamine","indication":"Treatment-resistant depression (TRD)","status":"marketed"},{"name":"JNJ-77242113","genericName":"JNJ-77242113","slug":"jnj-77242113","indication":"Schizophrenia","status":"phase_3"},{"name":"Matching placebo to Quetiapine XR","genericName":"Matching placebo to Quetiapine XR","slug":"matching-placebo-to-quetiapine-xr","indication":"Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial)","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"ODV 25 mg","genericName":"ODV 25 mg","slug":"odv-25-mg","indication":"Chronic Hepatitis C (genotypes 1–6)","status":"discontinued"},{"name":"DRV/COBI FDC","genericName":"DRV/COBI FDC","slug":"drv-cobi-fdc","indication":"HIV-1 infection in treatment-naive and treatment-experienced patients","status":"phase_3"},{"name":"ExPEC9V","genericName":"ExPEC9V","slug":"expec9v","indication":"Prevention of urinary tract infections caused by ExPEC","status":"phase_3"},{"name":"Odalasvir 25 mg","genericName":"Odalasvir 25 mg","slug":"odalasvir-25-mg","indication":"Chronic hepatitis C virus infection (genotypes 1–6)","status":"discontinued"},{"name":"Odalasvir 75 mg","genericName":"Odalasvir 75 mg","slug":"odalasvir-75-mg","indication":"Chronic hepatitis C (genotype 1)","status":"discontinued"},{"name":"epoetin alfa + packed RBC transfusion","genericName":"epoetin alfa + packed RBC transfusion","slug":"epoetin-alfa-packed-rbc-transfusion","indication":"Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"infectious","drugs":[{"name":"Antihyperglycemic agent(s)","genericName":"Antihyperglycemic agent(s)","slug":"antihyperglycemic-agent-s","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Metformin immediate release","genericName":"Metformin immediate release","slug":"metformin-immediate-release","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Sulfonylureas (SU)","genericName":"Sulfonylureas (SU)","slug":"sulfonylureas-su","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"AAVCAGsCD59","genericName":"AAVCAGsCD59","slug":"aavcagscd59","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CNTO 6785","genericName":"CNTO 6785","slug":"cnto-6785","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-aticaprant","genericName":"14C-aticaprant","slug":"14c-aticaprant","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AL-335","genericName":"AL-335","slug":"al-335","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ARV Background Regimen","genericName":"ARV Background Regimen","slug":"arv-background-regimen","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Active reference comparator","genericName":"Active reference comparator","slug":"active-reference-comparator","phase":"phase_3","mechanism":"Unable to determine specific mechanism without drug identity.","indications":[],"catalyst":""},{"name":"Canagliflozin 300 mg","genericName":"Canagliflozin 300 mg","slug":"canagliflozin-300-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Candin","genericName":"Candin","slug":"candin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cilta-cel","genericName":"Cilta-cel","slug":"cilta-cel","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dara SC","genericName":"Dara SC","slug":"dara-sc","phase":"phase_3","mechanism":"Dara SC (daratumumab subcutaneous) is a monoclonal antibody that targets CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab IV","genericName":"Daratumumab IV","slug":"daratumumab-iv","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab SC","genericName":"Daratumumab SC","slug":"daratumumab-sc","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"JNJ-67835989","genericName":"JNJ-67835989","slug":"jnj-67835989","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ODV 100 mg","genericName":"ODV 100 mg","slug":"odv-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ODV 25 mg","genericName":"ODV 25 mg","slug":"odv-25-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic Hepatitis C (genotypes 1–6)"],"catalyst":""},{"name":"PP1M","genericName":"PP1M","slug":"pp1m","phase":"phase_3","mechanism":"PP1M is a phosphodiesterase 10 (PDE10) inhibitor that increases intracellular cyclic nucleotide levels to modulate neuronal signaling.","indications":["Schizophrenia"],"catalyst":""},{"name":"Treatment C (placebo)","genericName":"Treatment C (placebo)","slug":"treatment-c-placebo","phase":"marketed","mechanism":"Placebo has no active pharmacological mechanism; it produces therapeutic effects through psychological and physiological expectation.","indications":["Used as control comparator in clinical trials across all therapeutic areas"],"catalyst":""},{"name":"VEN","genericName":"VEN","slug":"ven","phase":"marketed","mechanism":"Venetoclax is a selective inhibitor of the anti-apoptotic protein BCL-2 that promotes cancer cell death by restoring apoptosis.","indications":["Chronic lymphocytic leukemia (CLL), treatment-naïve and relapsed/refractory","Acute myeloid leukemia (AML), newly diagnosed in patients ≥75 years or unfit for intensive chemotherapy","Small lymphocytic lymphoma (SLL), relapsed/refractory"],"catalyst":""},{"name":"Xilonix","genericName":"Xilonix","slug":"xilonix","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"11C-JNJ-63779586","genericName":"11C-JNJ-63779586","slug":"11c-jnj-63779586","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-JNJ-56136379","genericName":"14C-JNJ-56136379","slug":"14c-jnj-56136379","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-bleximenib","genericName":"14C-bleximenib","slug":"14c-bleximenib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-lazertinib","genericName":"14C-lazertinib","slug":"14c-lazertinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"18F-JNJ-64326067","genericName":"18F-JNJ-64326067","slug":"18f-jnj-64326067","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"5-Flurouracil","genericName":"5-Flurouracil","slug":"5-flurouracil","phase":"phase_3","mechanism":"5-Fluorouracil is a pyrimidine analog that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and causing cell death.","indications":["Colorectal cancer","Breast cancer","Gastric cancer","Pancreatic cancer","Head and neck cancer"],"catalyst":""},{"name":"AAV5-hRKp.RPGR","genericName":"AAV5-hRKp.RPGR","slug":"aav5-hrkp-rpgr","phase":"phase_2","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"ARX517","genericName":"ARX517","slug":"arx517","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Abiraterone Acetate (AA)","genericName":"Abiraterone Acetate (AA)","slug":"abiraterone-acetate-aa","phase":"phase_3","mechanism":"Abiraterone acetate inhibits CYP17A1, a key enzyme in androgen synthesis, thereby reducing testosterone production in patients with castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer (mCRPC)","High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy)"],"catalyst":""},{"name":"Abiraterone acetate and prednisone","genericName":"Abiraterone acetate and prednisone","slug":"abiraterone-acetate-and-prednisone","phase":"phase_3","mechanism":"Abiraterone acetate inhibits CYP17A1 to block androgen synthesis, while prednisone suppresses ACTH-driven compensatory steroid production in castration-resistant prostate cancer.","indications":["Metastatic castration-resistant prostate cancer","High-risk castration-sensitive prostate cancer (in combination with androgen deprivation therapy)"],"catalyst":""},{"name":"Abiraterone: Treatment A","genericName":"Abiraterone: Treatment A","slug":"abiraterone-treatment-a","phase":"phase_1","mechanism":"Inhibits CYP17, a key enzyme in the biosynthesis of androgens.","indications":["Prostate cancer"],"catalyst":""},{"name":"Abiraterone: Treatment C","genericName":"Abiraterone: Treatment C","slug":"abiraterone-treatment-c","phase":"phase_1","mechanism":"CYP17 inhibitor","indications":["Prostate cancer"],"catalyst":""},{"name":"Abiraterone: Treatment D","genericName":"Abiraterone: Treatment D","slug":"abiraterone-treatment-d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ami-HC","genericName":"Ami-HC","slug":"ami-hc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ami-HC-CF","genericName":"Ami-HC-CF","slug":"ami-hc-cf","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ami-LC","genericName":"Ami-LC","slug":"ami-lc","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Amivantamab IV","genericName":"Amivantamab IV","slug":"amivantamab-iv","phase":"phase_2","mechanism":"Targeting EGFR","indications":["Non-small cell lung cancer"],"catalyst":""},{"name":"Amivantamab Intravenous","genericName":"Amivantamab Intravenous","slug":"amivantamab-intravenous","phase":"phase_3","mechanism":"Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.","indications":["Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations","EGFR-mutant NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors"],"catalyst":""},{"name":"Amivantamab SC","genericName":"Amivantamab SC","slug":"amivantamab-sc","phase":"phase_2","mechanism":"Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.","indications":["Metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation","Locally advanced or metastatic non-small cell lung cancer, EGFR exon 20 insertion mutation"],"catalyst":""},{"name":"Antidepressant","genericName":"Antidepressant","slug":"antidepressant","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antihyperglycemic agent(s)","genericName":"Antihyperglycemic agent(s)","slug":"antihyperglycemic-agent-s","phase":"phase_3","mechanism":"Antihyperglycemic agents work by reducing blood glucose levels through various mechanisms such as enhancing insulin secretion, improving insulin sensitivity, or reducing hepatic glucose production.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Apixaban 2.5 mg","genericName":"Apixaban 2.5 mg","slug":"apixaban-2-5-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Aticaprant Therapeutic Dose","genericName":"Aticaprant Therapeutic Dose","slug":"aticaprant-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Atomoxetine (ATO)","genericName":"Atomoxetine (ATO)","slug":"atomoxetine-ato","phase":"marketed","mechanism":"Atomoxetine selectively inhibits the reuptake of norepinephrine in the central nervous system, increasing norepinephrine availability at synapses.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults","ADHD-related symptoms in patients with comorbid conditions"],"catalyst":""},{"name":"BCG Vesiculture","genericName":"BCG Vesiculture","slug":"bcg-vesiculture","phase":"phase_3","mechanism":"BCG Vesiculture is a live attenuated Bacillus Calmette-Guérin vaccine formulation designed to stimulate innate and adaptive immune responses against bladder cancer.","indications":["Non-muscle invasive bladder cancer (NMIBC), high-grade urothelial carcinoma"],"catalyst":""},{"name":"Bermekimab Monoclonal Antibody","genericName":"Bermekimab Monoclonal Antibody","slug":"bermekimab-monoclonal-antibody","phase":"phase_2","mechanism":"Bermekimab is a monoclonal antibody that blocks IL-1β, a key pro-inflammatory cytokine, to reduce inflammation and immune activation.","indications":["Inflammatory conditions (Phase 2 development)"],"catalyst":""},{"name":"Best Supportive Care (BSC)","genericName":"Best Supportive Care (BSC)","slug":"best-supportive-care-bsc","phase":"phase_3","mechanism":"Best Supportive Care (BSC) is a control or comparator arm in clinical trials that provides standard medical management and symptom relief without the investigational drug.","indications":[],"catalyst":""},{"name":"Bridging Therapy","genericName":"Bridging Therapy","slug":"bridging-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Canagliflozin tablets","genericName":"Canagliflozin tablets","slug":"canagliflozin-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Canagliflozin, 100 mg","genericName":"Canagliflozin, 100 mg","slug":"canagliflozin-100-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Concerta AG formulation","genericName":"Concerta AG formulation","slug":"concerta-ag-formulation","phase":"phase_2","mechanism":"Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Concerta EG formulation","genericName":"Concerta EG formulation","slug":"concerta-eg-formulation","phase":"phase_2","mechanism":"Methylphenidate acts as a norepinephrine-dopamine reuptake inhibitor.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"Cosentyx","genericName":"Cosentyx","slug":"cosentyx","phase":"marketed","mechanism":"Interleukin-17A","indications":["Ankylosing spondylitis","Non-radiographic axial spondyloarthritis","Plaque psoriasis","Psoriatic arthritis","Pustular psoriasis"],"catalyst":""},{"name":"DRV/COBI FDC","genericName":"DRV/COBI FDC","slug":"drv-cobi-fdc","phase":"phase_3","mechanism":"DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication.","indications":["HIV-1 infection in treatment-naive and treatment-experienced patients"],"catalyst":""},{"name":"Dapoxetine hydrochloride","genericName":"Dapoxetine hydrochloride","slug":"dapoxetine-hydrochloride","phase":"phase_3","mechanism":"Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the central nervous system to delay ejaculation.","indications":["Premature ejaculation in men aged 18-64 years"],"catalyst":""},{"name":"Dara IV","genericName":"Dara IV","slug":"dara-iv","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Daratumumab SC: daratumumab + rHuPH20","genericName":"Daratumumab SC: daratumumab + rHuPH20","slug":"daratumumab-sc-daratumumab-rhuph20","phase":"phase_3","mechanism":"Daratumumab is a monoclonal antibody that binds to CD38 on multiple myeloma cells and triggers their destruction through multiple immune mechanisms, while rHuPH20 enhances subcutaneous bioavailability.","indications":["Multiple myeloma (newly diagnosed and relapsed/refractory)","Light chain myeloma"],"catalyst":""},{"name":"Dexamethasone 20 mg","genericName":"Dexamethasone 20 mg","slug":"dexamethasone-20-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Esketamine 56 mg","genericName":"Esketamine 56 mg","slug":"esketamine-56-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ExPEC9V","genericName":"ExPEC9V","slug":"expec9v","phase":"phase_3","mechanism":"ExPEC9V is a vaccine designed to stimulate immune responses against extraintestinal pathogenic E. coli (ExPEC) strains.","indications":["Prevention of urinary tract infections caused by ExPEC","Prevention of bacteremia and invasive infections caused by ExPEC"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR","genericName":"Genetic: AAV5-hRKp.RPGR","slug":"genetic-aav5-hrkp-rpgr","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","genericName":"Genetic: AAV5-hRKp.RPGR Intermediate Dose","slug":"genetic-aav5-hrkp-rpgr-intermediate-dose","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Genetic: AAV5-hRKp.RPGR Low Dose","genericName":"Genetic: AAV5-hRKp.RPGR Low Dose","slug":"genetic-aav5-hrkp-rpgr-low-dose","phase":"phase_3","mechanism":"AAV5-hRKp.RPGR is a gene therapy that delivers a functional copy of the RPGR gene into retinal cells to restore vision in patients with X-linked retinitis pigmentosa.","indications":["X-linked retinitis pigmentosa (XLRP) caused by RPGR mutations"],"catalyst":""},{"name":"Guselkumab Dose 1","genericName":"Guselkumab Dose 1","slug":"guselkumab-dose-1","phase":"phase_3","mechanism":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"Guselkumab Intravenous","genericName":"Guselkumab Intravenous","slug":"guselkumab-intravenous","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Guselkumab Subcutaneous","genericName":"Guselkumab Subcutaneous","slug":"guselkumab-subcutaneous","phase":"phase_3","mechanism":"Guselkumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease"],"catalyst":""},{"name":"HD quadrivalent influenza vaccine","genericName":"HD quadrivalent influenza vaccine","slug":"hd-quadrivalent-influenza-vaccine","phase":"phase_3","mechanism":"HD quadrivalent influenza vaccine stimulates immune responses against four strains of influenza virus using a high-dose antigen formulation to enhance protection, particularly in older adults.","indications":["Prevention of influenza in adults aged 65 years and older","Prevention of influenza in adults aged 18 years and older (Phase 3 evaluation)"],"catalyst":""},{"name":"Imvanex","genericName":"Imvanex","slug":"imvanex","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Intravenous Esketamine","genericName":"Intravenous Esketamine","slug":"intravenous-esketamine","phase":"marketed","mechanism":"Intravenous esketamine is an NMDA receptor antagonist that rapidly blocks glutamate signaling in the brain to produce fast-acting antidepressant effects.","indications":["Treatment-resistant depression (TRD)","Major depressive disorder with acute suicidal ideation or behavior"],"catalyst":""},{"name":"JNJ-42756493: Part 1","genericName":"JNJ-42756493: Part 1","slug":"jnj-42756493-part-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911","genericName":"JNJ-54861911","slug":"jnj-54861911","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-54861911-Therapeutic Dose","genericName":"JNJ-54861911-Therapeutic Dose","slug":"jnj-54861911-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-55375515 Dose Level 5","genericName":"JNJ-55375515 Dose Level 5","slug":"jnj-55375515-dose-level-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-61393215","genericName":"JNJ-61393215","slug":"jnj-61393215","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-63623872 600 mg","genericName":"JNJ-63623872 600 mg","slug":"jnj-63623872-600-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-63723283","genericName":"JNJ-63723283","slug":"jnj-63723283","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 1","genericName":"JNJ-64565111 Dose Level 1","slug":"jnj-64565111-dose-level-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 2","genericName":"JNJ-64565111 Dose Level 2","slug":"jnj-64565111-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64565111 Dose Level 3","genericName":"JNJ-64565111 Dose Level 3","slug":"jnj-64565111-dose-level-3","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-64991524 Dose Level 8","genericName":"JNJ-64991524 Dose Level 8","slug":"jnj-64991524-dose-level-8","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67571244","genericName":"JNJ-67571244","slug":"jnj-67571244","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-67953964","genericName":"JNJ-67953964","slug":"jnj-67953964","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-68284528","genericName":"JNJ-68284528","slug":"jnj-68284528","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JNJ-77242113","genericName":"JNJ-77242113","slug":"jnj-77242113","phase":"phase_3","mechanism":"JNJ-77242113 is a selective inhibitor of phosphodiesterase 10A (PDE10A) that increases intracellular signaling in the brain to modulate neuronal activity.","indications":["Schizophrenia","Bipolar disorder (exploratory)"],"catalyst":""},{"name":"JNJ-78934804","genericName":"JNJ-78934804","slug":"jnj-78934804","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"JNJ-79635322","genericName":"JNJ-79635322","slug":"jnj-79635322","phase":"phase_3","mechanism":"JNJ-79635322 is a monoclonal antibody that targets and inhibits IL-17A, a pro-inflammatory cytokine involved in immune-mediated inflammatory diseases.","indications":["Psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"JNJ-95475939","genericName":"JNJ-95475939","slug":"jnj-95475939","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ketoconazole 200 mg","genericName":"Ketoconazole 200 mg","slug":"ketoconazole-200-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Leucovorin calcium/Levoleucovorin","genericName":"Leucovorin calcium/Levoleucovorin","slug":"leucovorin-calcium-levoleucovorin","phase":"phase_3","mechanism":"Leucovorin calcium and levoleucovorin are reduced folate cofactors that enhance the efficacy of antimetabolite chemotherapy agents by providing essential one-carbon units for nucleotide synthesis.","indications":["Metastatic colorectal cancer (in combination with fluorouracil)","High-dose methotrexate toxicity rescue","Fluorouracil-based chemotherapy potentiation"],"catalyst":""},{"name":"Matching Placebo to JNJ-77242113","genericName":"Matching Placebo to JNJ-77242113","slug":"matching-placebo-to-jnj-77242113","phase":"phase_3","mechanism":"This is a placebo control formulation matching the inactive vehicle and appearance of JNJ-77242113 for blinded clinical trial comparison.","indications":[],"catalyst":""},{"name":"Matching Placebo to Ustekinumab","genericName":"Matching Placebo to Ustekinumab","slug":"matching-placebo-to-ustekinumab","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration route of ustekinumab for blinded clinical trial comparison.","indications":[],"catalyst":""},{"name":"Matching placebo to Quetiapine XR","genericName":"Matching placebo to Quetiapine XR","slug":"matching-placebo-to-quetiapine-xr","phase":"phase_3","mechanism":"This is a matching placebo formulation designed to mimic Quetiapine XR (an atypical antipsychotic) for blinded clinical trial purposes.","indications":["Control arm in Phase 3 clinical trials of Quetiapine XR (schizophrenia, bipolar disorder, or major depressive disorder, depending on the specific trial)"],"catalyst":""},{"name":"Matching placebo to Seltorexant","genericName":"Matching placebo to Seltorexant","slug":"matching-placebo-to-seltorexant","phase":"phase_3","mechanism":"This is a matching placebo control formulation designed to mimic Seltorexant, an orexin 2 receptor antagonist used in sleep disorder trials.","indications":["Matching placebo control for Seltorexant clinical trials (not a therapeutic agent)"],"catalyst":""},{"name":"Metformin immediate release","genericName":"Metformin immediate release","slug":"metformin-immediate-release","phase":"phase_3","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.","indications":["Type 2 diabetes mellitus","Prediabetes (prevention of progression to type 2 diabetes)"],"catalyst":""},{"name":"Nipocalimab SC-LIV","genericName":"Nipocalimab SC-LIV","slug":"nipocalimab-sc-liv","phase":"phase_3","mechanism":"Nipocalimab is a subcutaneous monoclonal antibody that blocks neonatal Fc receptor (FcRn) to reduce pathogenic immunoglobulin levels in autoimmune conditions.","indications":["Generalized myasthenia gravis (gMG)","IgG-mediated autoimmune conditions"],"catalyst":""},{"name":"Odalasvir 25 mg","genericName":"Odalasvir 25 mg","slug":"odalasvir-25-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic hepatitis C virus infection (genotypes 1–6)"],"catalyst":""},{"name":"Odalasvir 75 mg","genericName":"Odalasvir 75 mg","slug":"odalasvir-75-mg","phase":"discontinued","mechanism":"Odalasvir inhibits hepatitis C virus NS5A protein to block viral replication and assembly.","indications":["Chronic hepatitis C (genotype 1)","Chronic hepatitis C (treatment-naïve and treatment-experienced)","Chronic hepatitis C (Japanese population)"],"catalyst":""},{"name":"PCI-32765 (Ibrutinib)","genericName":"PCI-32765 (Ibrutinib)","slug":"pci-32765-ibrutinib","phase":"phase_3","mechanism":"Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell receptor signaling and reduces proliferation of malignant B cells.","indications":["Chronic lymphocytic leukemia (CLL)","Mantle cell lymphoma (MCL)","Marginal zone lymphoma (MZL)","Waldenstrom macroglobulinemia (WM)"],"catalyst":""},{"name":"PP6M injection Dose 1","genericName":"PP6M injection Dose 1","slug":"pp6m-injection-dose-1","phase":"phase_3","mechanism":"PP6M is a long-acting injectable contraceptive that prevents pregnancy through hormonal suppression of ovulation.","indications":["Contraception in women of reproductive age"],"catalyst":""},{"name":"Placebo (20% Intralipid)","genericName":"Placebo (20% Intralipid)","slug":"placebo-20-intralipid","phase":"phase_3","mechanism":"Placebo (20% Intralipid) does not have an active pharmacological effect; it serves as a control in clinical trials.","indications":[],"catalyst":""},{"name":"Placebo and prednisone","genericName":"Placebo and prednisone","slug":"placebo-and-prednisone","phase":"phase_3","mechanism":"This is a comparator arm combining placebo with prednisone, a corticosteroid that suppresses immune function and reduces inflammation.","indications":["Active comparator arm in phase 3 clinical trial (specific indication unknown)"],"catalyst":""},{"name":"Placebo for Niraparib","genericName":"Placebo for Niraparib","slug":"placebo-for-niraparib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Niraparib"],"catalyst":""},{"name":"Placebo for guselkumab","genericName":"Placebo for guselkumab","slug":"placebo-for-guselkumab","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Standard of Care Treatment","genericName":"Standard of Care Treatment","slug":"standard-of-care-treatment","phase":"phase_3","mechanism":"This drug works by inhibiting the PD-1 receptor, which helps the immune system recognize and attack cancer cells.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma","Urothelial carcinoma","Melanoma","Renal cell carcinoma"],"catalyst":""},{"name":"Sulfonylureas (SU)","genericName":"Sulfonylureas (SU)","slug":"sulfonylureas-su","phase":"phase_3","mechanism":"Sulfonylureas stimulate insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Sulphonylruea","genericName":"Sulphonylruea","slug":"sulphonylruea","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sulphonylurea","genericName":"Sulphonylurea","slug":"sulphonylurea","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TAR-200","genericName":"TAR-200","slug":"tar-200","phase":"phase_3","mechanism":"TAR-200 is a monoclonal antibody targeting the PD-1 receptor.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive","Metastatic melanoma"],"catalyst":""},{"name":"TAR-210","genericName":"TAR-210","slug":"tar-210","phase":"phase_3","mechanism":"TAR-210 is a bispecific antibody targeting the PD-1 and LAG-3 immune checkpoint proteins.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Treatment C: abiraterone acetate","genericName":"Treatment C: abiraterone acetate","slug":"treatment-c-abiraterone-acetate","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Treatment sequence 2","genericName":"Treatment sequence 2","slug":"treatment-sequence-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ustekinumab - Half-Standard Dosage","genericName":"Ustekinumab - Half-Standard Dosage","slug":"ustekinumab-half-standard-dosage","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the action of interleukin-12 and interleukin-23, which are proteins involved in inflammation.","indications":["Moderate to severe plaque psoriasis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"Ustekinumab IV","genericName":"Ustekinumab IV","slug":"ustekinumab-iv","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Ustekinumab SC","genericName":"Ustekinumab SC","slug":"ustekinumab-sc","phase":"phase_3","mechanism":"Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of immune-mediated inflammatory responses.","indications":["Plaque psoriasis","Psoriatic arthritis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"[18F]MNI-1020","genericName":"[18F]MNI-1020","slug":"18f-mni-1020","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"epoetin alfa + packed RBC transfusion","genericName":"epoetin alfa + packed RBC transfusion","slug":"epoetin-alfa-packed-rbc-transfusion","phase":"phase_3","mechanism":"Epoetin alfa stimulates erythropoiesis by binding to the erythropoietin receptor, promoting the production of red blood cells.","indications":["Treatment of anemia associated with chronic kidney disease, chemotherapy-induced anemia, and HIV-associated anemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPdWpfRE9DNFBKQTFKRXZxU19sY0tFVnM0NGFfVjRTdkxSSDY5OW9fRzZEMjhMWEE2Vkp2S1dha3RjZU1xTVBhcENZbjE2aHRMTW5iU0tydFRKSUREWHBHRUwzWWxVTGQxRjAza1BJaktUTFNtaUE4allvLU14WU0ybWZSMm9zOXVEVnNWY1Y4ckFRajlUendLZU1LSUZFbTZ6VTRpN2ZNYkUzRHFLdlZWakZ2bjZiX18xRVIzYjNRNld5QmQ2cEdqYWswdHJCVzk3Y0s5YS1DYVZwbVlGb1NvMmpvUjNQamhhaEx1SGlGeXdyRUN0SlhvbkJjYkF2dTd4bTktWFZOalQtRTJiTVVOampJZmVNOEV2eG1MV1pXWEpYRlduMWpZSnFnVTVHSWE2TjV4YVhCN2JIX1Z1dkFTZVpqblA5endudkRoeHRDdTdzZw?oc=5","date":"2026-03-25","type":"pipeline","source":"Barchart.com","summary":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - B","headline":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNeDdmNVZfMHF2bW9KX1dSbnhuSnc3M1UwVXhUUnIwb3FSVjZPVHc5YjdESkFVTjNkbEQyUkRtT2pkamdHdFAzRjQ5TDVFT0x4T2I4OGxjeERrYmNTdnhmS1pTc1BSSDl0TlM2elRYWmJQZW9CMTAyVnFJQXZhUjJlRzlCWk9zZnlEMTZ6VGE5MlgtREhtWExEb3NfSWZ3Ri13YzIzLVJvWG1qVjJwNy1ZN1IzVUp5UGJ3ZzhsT3lsNHRSMFRINUFmcjdIUGE?oc=5","date":"2023-11-20","type":"deal","source":"respiratory-therapy.com","summary":"Janssen, Boston University to Partner on COPD Research - respiratory-therapy.com","headline":"Janssen, Boston University to Partner on COPD Research - respiratory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBPQmxzQmdfNWlRbDhfSHZkS1VsZ1ZuTkxmRjNIeVo3YWhGMXoxd29UYThwa3pzRTVSRUlBRGY2RUhwdl90Z2JLVUwtalFMYlpkRExpWjVVUHNianRON3M3Q1JJRWU3Zw?oc=5","date":"2023-11-02","type":"pipeline","source":"National Center for Advancing Translational Sciences (NCATS) (.gov)","summary":"NCATS Funding Available to Repurpose Existing Drugs - National Center for Advancing Translational Sciences (NCATS) (.gov)","headline":"NCATS Funding Available to Repurpose Existing Drugs - National Center for Advancing Translational Sciences (NCATS) (.gov","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPdnRxWFV3SFZPbGZDVUs4djZLUmhWNHV5Q2k1UTU4cU95UkFGaC01NXMtLXR6NkNGZnRTS0hZS3RmdzUxbGdWZ2x2Nml0LU9WdlR0MTl0NjM4VENobTZ2NGZUNXpfal91S2pROEpxV0xUNjNaOUxqbEFSZGxmQlZTb3FEZzY0TVVDZlk3Y1A5NExNdExjWW5LZnRZRkZibXNQU1B1T0JUZ0FqLXp4S3c?oc=5","date":"2023-08-14","type":"regulatory","source":"European Pharmaceutical Review","summary":"FDA approval for Janssen’s prostate cancer treatment - European Pharmaceutical Review","headline":"FDA approval for Janssen’s prostate cancer treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOYnZjTkNKdkFYOHVHc3dRQzVWdkR6Z1hIMXQ0V25YTnRfd0Y0bFN0WDRFNDJfMGpreFllbTJsT3BCTjdZeUVMZGo2OWx5TVpNV2NkcS1Kd3ZwZU5WWV93Z0V0SGlyMW1oS0xUbWczXzN1aUpTeFE0YzF4X3ozUXlEMDRGNk0yRzJhV0ZCdVlZZ09vRDQ?oc=5","date":"2023-03-29","type":"pipeline","source":"PR Newswire","summary":"Janssen Provides Portfolio Update - PR Newswire","headline":"Janssen Provides Portfolio Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUkdqczRJWW5SZmRqcGVzOTBuQTRydzZTQ0NNaEppSEg4cGh3V1ZVYmdHZURuNW4yc2h4a3lPR1NkdHI3cGhIb2dVUXc5RjJlUi1SVnk3V2JpVHBsNm5GLVh5ZnY3SFpyVGM5ZlNEMUQtTzJaRXhkblExVGVfRm1jZE5XbjdiOHRQaHNRYm1MRFFRckZodjVXZlR5amFrZ25fcjAwWDktaHlBZw?oc=5","date":"2022-08-09","type":"trial","source":"clinicalleader.com","summary":"Janssen's 3 Strategies For Improving Clinical Trials In Neuroscience - clinicalleader.com","headline":"Janssen's 3 Strategies For Improving Clinical Trials In Neuroscience","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQN1NYbWkyLWo5b3NNM0dQYXdIU1hfdHE4UVVSQzktVmZWc3VNbXhhUjExNlN0X2dwSlp6TGhmbW1TTUxRQ1J0eDhORVhKY0xQRFJXR2NOeUJTTzdRY1liOTI0c1RNUDFUX21tSXFWYzVfRHRyZDNtT251MFVLdUU1OXZNcldBeGVYSk9uRTVvb0h3OVo5Vm9pR1lyeC0wX1B6alVNeFRsajkwQTlXUGFHSElKSkNqRTd5V2FXY2lRZkk0MWwyelE?oc=5","date":"2022-01-03","type":"trial","source":"Fierce Pharma","summary":"Janssen Takes Multifaceted Approach to Ensuring Diversity, Equity, and Inclusion in its COVID-19 Vaccine Trial - Fierce Pharma","headline":"Janssen Takes Multifaceted Approach to Ensuring Diversity, Equity, and Inclusion in its COVID-19 Vaccine Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOU1ZCaDB3SG5MZlQyNnFMY01QSjZkbkVnN0Q3S0UwRlBDa2JoWHNsUE5DTnpoTWJ0SFpibXBCMVp0Z25ZaGx5WnVKNEluOV90aEM4ZWpkQ3hsSjBUWENQdGNMSHlSV28zNnhyZjktcE1RQzQxRmtmS2k5R0E3ZlZCWjFQeV9xWVFfUThKbFhBaTJpNzJYVDNDUXJ2c0k0Z3NfRWUtVzM4OE9Wb1QyRDBieTZaVUUtSHdtczhlalZ4ODBCeTdVVC1zazQ0VUFrNVZ5ZC10UzRjdlpULU1hMkl0Xw?oc=5","date":"2020-01-10","type":"pipeline","source":"Business Wire","summary":"Janssen Expands Research & Development Presence with Major Investment in South San Francisco - Business Wire","headline":"Janssen Expands Research & Development Presence with Major Investment in South San Francisco","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxPZnZMNWM3VXVQcVVFYUVpZjByR0xBaVZGakRycTkzbDVRMHlLbnBmelpQWjdKNGpqNEhQcDB4N1c1ZnUxWmR0aWtzU3dJbWR6d2ZCY0d2VXUtNjlrSWtqakxnYkZYNGhXbGl5YmZhLUZMOHVUU1ZYV2tJbXFTd1dfWkNWVENrNGlKekswNE9ZbzA4Vlh0amVSTlJyQlJkQXl4dnhtRXVIVHB4QTVfTC1BRW5xY194c0NGWWJ6THZGMDZQQ1JCWl92VzNKdUxLVFlkbE91VDliX0lnWWJvV2dPdUt0NVNCNU84UmZFT1Z2dlVZWXNOdjl0NHUwWkQwalg0RFNSVVRhSk43WmpNa3diaThUQmRHeGd5WHE3Zm1YWDZqN3Nlc3pqZGduWFJJaHpKLWNJWnBQamJOdURHTDlIUkZiRTlTZ19nY0tv?oc=5","date":"2018-10-04","type":"deal","source":"PR Newswire","summary":"Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a New Treatment for Chronic Hepatitis B Viral Infection - PR Newswire","headline":"Janssen Announces Exclusive, Worldwide License Agreement With Arrowhead Pharmaceuticals to Develop and Commercialize a N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE5JaVFjN0hDRUtjZ1pZZk1JVmNSN29yQURwRVR6Z2lRV3RicjlabGt4ZXhFemlqYi1xWFJoRE5HbFlmczVTb094QTUyZFQwV2lsVF9Td3E1STFKSEU?oc=5","date":"2017-03-23","type":"pipeline","source":"UC San Diego Today","summary":"A Dose of Research - UC San Diego Today","headline":"A Dose of Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPQWRfNHkzX09kY1pHUlMxdG5HbWUzMVhrTXByNF9LZFdDMDhIMEx5cGxVclRQVE9QSkdwM3FFY2V1dXdHTUc5Q0VQZUZSVmRfN3BqVVJMTUZ1SWJYOThudVpRcTByYW1lX3ZxdEU2cjgyenpzYlV6QUpmeXM4dGI1NlR1WVQzZGVRWGpXOF9FUXFxcW9CSklZM1BlVmVIeUNY?oc=5","date":"2013-04-08","type":"pipeline","source":"MIT Sloan Management Review","summary":"How Pharmaceuticals Can Avoid the Side Effects of Social Media - MIT Sloan Management Review","headline":"How Pharmaceuticals Can Avoid the Side Effects of Social Media","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxNVmk0WG5ZSlYtN1VUNTJ5SzdnNmN3WHpqTTRTZnp6NEZIbmdpanRLTXdCcWN4Mlh4ZW5lMlAtZDdaTE5meXc0VHIzUTFubkl2OS1hY21wdlJNM1Yxdkg3SGJKMS1yQVNud1dmY1lveDl1MEJSYXR3Sm9KOWxMN2VGeU1KNWtGQlhNVjVlck0xdi1ZOTFNcFhMVUZUTERBNGFpaXhjVmJhTmgxUHMtZjRBbWZUVUs0M0R2YlktbW1ncl9PSVp1Y1FWVUFhTnNyZkJtcHhjTjBsODdGZUpibUxIZGE2WndicGx2M1ZDNENkdHVfMEZFcWpOaXRDNmg0dEM3SnpuSC1XYXQ?oc=5","date":"2012-11-15","type":"trial","source":"PR Newswire","summary":"Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank - PR Newswire","headline":"Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databa","sentiment":"neutral"}],"patents":[],"drugCount":115,"phaseCounts":{"phase_1":30,"phase_2":19,"phase_3":48,"marketed":13,"discontinued":5},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}